• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

纤维蛋白凝胶增强嵌合抗原受体T细胞对胶质母细胞瘤的抗肿瘤作用。

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.

作者信息

Ogunnaike Edikan A, Valdivia Alain, Yazdimamaghani Mostafa, Leon Ernesto, Nandi Seema, Hudson Hannah, Du Hongwei, Khagi Simon, Gu Zhen, Savoldo Barbara, Ligler Frances S, Hingtgen Shawn, Dotti Gianpietro

机构信息

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.

Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, Raleigh, NC 27695, USA.

出版信息

Sci Adv. 2021 Oct 8;7(41):eabg5841. doi: 10.1126/sciadv.abg5841. Epub 2021 Oct 6.

DOI:10.1126/sciadv.abg5841
PMID:34613775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8494441/
Abstract

Regional delivery of chimeric antigen receptor (CAR) T cells in glioblastoma represents a rational therapeutic approach as an alternative to intravenous administration to avoid the blood-brain barrier impediment. Here, we developed a fibrin gel that accommodates CAR-T cell loading and promotes their gradual release. Using a model of subtotal glioblastoma resection, we demonstrated that the fibrin-based gel delivery of CAR-T cells within the surgical cavity enables superior antitumor activity compared to CAR-T cells directly inoculated into the tumor resection cavity.

摘要

在胶质母细胞瘤中，嵌合抗原受体（CAR）T细胞的局部递送是一种合理的治疗方法，可替代静脉给药以避免血脑屏障的阻碍。在此，我们开发了一种纤维蛋白凝胶，可容纳CAR-T细胞负载并促进其逐渐释放。使用胶质母细胞瘤次全切除模型，我们证明，与直接接种到肿瘤切除腔内的CAR-T细胞相比，在手术腔内基于纤维蛋白凝胶递送CAR-T细胞具有更强的抗肿瘤活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/8b8fbd0de883/sciadv.abg5841-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/21f0d1ae835d/sciadv.abg5841-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/351fa9ec71ed/sciadv.abg5841-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/5391b7a61b53/sciadv.abg5841-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/52d2a4fa0fd5/sciadv.abg5841-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/19a1bc25a038/sciadv.abg5841-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/8b8fbd0de883/sciadv.abg5841-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/21f0d1ae835d/sciadv.abg5841-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/351fa9ec71ed/sciadv.abg5841-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/5391b7a61b53/sciadv.abg5841-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/52d2a4fa0fd5/sciadv.abg5841-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/19a1bc25a038/sciadv.abg5841-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ebc/8494441/8b8fbd0de883/sciadv.abg5841-f6.jpg

相似文献

1
Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.纤维蛋白凝胶增强嵌合抗原受体T细胞对胶质母细胞瘤的抗肿瘤作用。
Sci Adv. 2021 Oct 8;7(41):eabg5841. doi: 10.1126/sciadv.abg5841. Epub 2021 Oct 6.
2
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.优化针对 IL13Rα2 的嵌合抗原受体 T 细胞，以提高对神经胶质瘤的抗肿瘤疗效。
Mol Ther. 2018 Jan 3;26(1):31-44. doi: 10.1016/j.ymthe.2017.10.002. Epub 2017 Oct 5.
3
Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.通过重编程肿瘤相关小胶质细胞和巨噬细胞增强胶质母细胞瘤免疫疗法的嵌合抗原受体 T 细胞。
ACS Nano. 2024 Apr 30;18(17):11165-11182. doi: 10.1021/acsnano.4c00050. Epub 2024 Apr 16.
4
Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives.用于胶质母细胞瘤的嵌合抗原受体T细胞：当前概念、挑战及未来展望
Neurology. 2021 Aug 3;97(5):218-230. doi: 10.1212/WNL.0000000000012193. Epub 2021 May 13.
5
Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.嵌合抗原受体 T 细胞疗法治疗多形性胶质母细胞瘤的研究进展。
Cancer Med. 2021 Aug;10(15):5019-5030. doi: 10.1002/cam4.4064. Epub 2021 Jun 19.
6
Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.嵌合抗原受体 T 细胞对 C57BL/6 小鼠 EGFRvIII 表达型脑胶质瘤的抗肿瘤疗效。
Biomed Pharmacother. 2019 May;113:108734. doi: 10.1016/j.biopha.2019.108734. Epub 2019 Mar 5.
7
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.转染 IL-15 的 GD2 靶向 CAR-T 细胞是胶质母细胞瘤有效且可行的临床治疗方法。
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005187.
8
Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma.嵌合抗原受体T细胞（CAR-T）疗法治疗胶质母细胞瘤的进展及与其他疗法联合应用的研究洞察
Int J Gen Med. 2023 Sep 11;16:4121-4141. doi: 10.2147/IJGM.S418837. eCollection 2023.
9
Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma.将IL7受体α信号传导整合到靶向B7H3的嵌合抗原受体T细胞的胞内结构域中可介导胶质母细胞瘤的抗肿瘤活性。
Cancer Immunol Immunother. 2024 Apr 15;73(6):98. doi: 10.1007/s00262-024-03685-7.
10
Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.抗 EGFR 变异 III 嵌合抗原受体 T 细胞治疗联合 PD-1 检查点阻断对小鼠模型胶质母细胞瘤的抗肿瘤作用。
Cell Immunol. 2020 Jun;352:104112. doi: 10.1016/j.cellimm.2020.104112. Epub 2020 Apr 9.

引用本文的文献

1
Hydrogels as advanced drug delivery platforms for cancer immunotherapy: promising innovations and future outlook.水凝胶作为癌症免疫治疗的先进药物递送平台：有前景的创新与未来展望。
J Nanobiotechnology. 2025 Jul 28;23(1):545. doi: 10.1186/s12951-025-03613-6.
2
CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.嵌合抗原受体T细胞疗法在脑恶性肿瘤中的应用：细胞转运与存活面临的障碍
Front Immunol. 2025 Jun 19;16:1596499. doi: 10.3389/fimmu.2025.1596499. eCollection 2025.
3
Targeting the glioblastoma resection margin with locoregional nanotechnologies.

本文引用的文献

1
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision.包被于可注射水凝胶中的 GD2 特异性 CAR T 细胞控制视网膜母细胞瘤并保留视力。
Nat Cancer. 2020 Oct;1(10):990-997. doi: 10.1038/s43018-020-00119-y. Epub 2020 Oct 12.
2
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.纳武利尤单抗对比贝伐珠单抗治疗复发性胶质母细胞瘤患者的效果：CheckMate 143 期随机临床试验。
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024.
3
Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.
利用局部纳米技术靶向胶质母细胞瘤切除边缘。
Nat Rev Clin Oncol. 2025 May 14. doi: 10.1038/s41571-025-01020-2.
4
Strategies for Altering Delivery Technologies to Optimize CAR Therapy.改变递送技术以优化嵌合抗原受体（CAR）疗法的策略。
Int J Mol Sci. 2025 Mar 30;26(7):3206. doi: 10.3390/ijms26073206.
5
Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus.通过溶瘤病毒递送肽-主要组织相容性复合体实现基于新抗原的肿瘤疫苗的广泛应用。
EMBO Mol Med. 2025 May;17(5):1118-1152. doi: 10.1038/s44321-025-00225-3. Epub 2025 Apr 7.
6
CAR-T therapy dilemma and innovative design strategies for next generation.嵌合抗原受体T细胞（CAR-T）疗法的困境与下一代创新设计策略
Cell Death Dis. 2025 Mar 27;16(1):211. doi: 10.1038/s41419-025-07454-x.
7
Injectable Tumoricidal Neural Stem Cell-Laden Hydrogel for Treatment of Glioblastoma Multiforme-An In Vivo Safety, Persistence, and Efficacy Study.用于治疗多形性胶质母细胞瘤的负载可注射杀肿瘤神经干细胞水凝胶——一项体内安全性、持久性和疗效研究
Pharmaceutics. 2024 Dec 24;17(1):3. doi: 10.3390/pharmaceutics17010003.
8
Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung.负载STING激动剂的可吸入纳米囊泡增强了CAR-T细胞对肺部实体瘤的活性。
Nat Commun. 2025 Jan 2;16(1):262. doi: 10.1038/s41467-024-55751-4.
9
Beyond the blood: expanding CAR T cell therapy to solid tumors.超越血液：将嵌合抗原受体T细胞疗法扩展至实体瘤
Nat Biotechnol. 2025 Apr;43(4):506-515. doi: 10.1038/s41587-024-02446-2. Epub 2024 Nov 12.
10
Emerging Cancer Immunotherapies: Cutting-Edge Advances and Innovations in Development.新兴癌症免疫疗法：开发中的前沿进展与创新。
Med Sci (Basel). 2024 Aug 28;12(3):43. doi: 10.3390/medsci12030043.
增强嵌合抗原受体 T 细胞在实体瘤中的疗效。
Clin Cancer Res. 2020 Jun 1;26(11):2444-2451. doi: 10.1158/1078-0432.CCR-19-1835. Epub 2020 Feb 3.
4
THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.THEMIS-SHP1 通过 4-1BB 招募调控嵌合抗原受体重定向 T 细胞的 LCK 介导的启动。
Cancer Cell. 2020 Feb 10;37(2):216-225.e6. doi: 10.1016/j.ccell.2019.12.014. Epub 2020 Jan 30.
5
Fibrin as a Multipurpose Physiological Platform for Bone Tissue Engineering and Targeted Delivery of Bioactive Compounds.纤维蛋白作为用于骨组织工程和生物活性化合物靶向递送的多功能生理平台。
Pharmaceutics. 2019 Oct 28;11(11):556. doi: 10.3390/pharmaceutics11110556.
6
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.B7-H3 重定向嵌合抗原受体 T 细胞靶向神经胶质瘤和神经球。
EBioMedicine. 2019 Sep;47:33-43. doi: 10.1016/j.ebiom.2019.08.030. Epub 2019 Aug 26.
7
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.嵌合抗原受体修饰的 T 细胞过继转移治疗胶质母细胞瘤患者中针对 EGFRvIII 的初步临床试验
J Immunother. 2019 May;42(4):126-135. doi: 10.1097/CJI.0000000000000260.
8
Engineered Mesenchymal Stem Cell/Nanomedicine Spheroid as an Active Drug Delivery Platform for Combinational Glioblastoma Therapy.工程化间充质干细胞/纳米医学球体作为联合胶质母细胞瘤治疗的主动药物递送平台。
Nano Lett. 2019 Mar 13;19(3):1701-1705. doi: 10.1021/acs.nanolett.8b04697. Epub 2019 Feb 21.
9
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B7-H3 治疗实体瘤，无毒性作用下的抗肿瘤反应。
Cancer Cell. 2019 Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002.
10
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds.图像引导下胶质母细胞瘤切除术及治疗性干细胞接种支架的颅内植入
J Vis Exp. 2018 Jul 16(137):57452. doi: 10.3791/57452.